Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431792 | 0.92 | MEN1 (0.41) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL16878106 | 0.92 | MEN1 (0.41) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL14463070 | 0.90 | — | — | |
| SCHEMBL11811890 | 0.90 | MEN1 (0.52) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Hydrochloric Acid SCHEMBL26131782 | 0.87 | MEN1 (0.38) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL16878072 | 0.87 | MEN1 (0.38) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL5423599 | 0.87 | MEN1 (0.38) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL16878247 | 0.85 | MEN1 (0.36) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL5426847 | 0.85 | MEN1 (0.42) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL16877793 | 0.85 | MEN1 (0.36) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8822459-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8614323-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2657235-A1 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-1942108-B1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-1961744-B1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20120328627-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-12-27 | — | — | US | disclosed |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8168783-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7951816-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1942108-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | CXCR4, CXCL12, CXCR3 | MEN1 1493/4885KMT2A 3189/4885KDM4E 4477/4885 |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | MEN1 3160/4885KMT2A 3667/4885KDM4E 4377/4885 |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR3, CXCR1 | MEN1 2594/4885KMT2A 3359/4885KDM4E 4606/4885 |
| US-20090118279-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CXCR1, CXCR3 | MEN1 2513/4885KMT2A 3385/4885KDM4E 3862/4885 |
| US-20110142856-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | CXCR4, CCR5, CXCL12 | MEN1 2047/4885KMT2A 3576/4885KDM4E 4387/4885 |
| US-20080009495-A1 | Compound Containing Basic Group and Use Thereof | CXCR4, CCR5, CXCR3 | MEN1 2163/4885KMT2A 3544/4885KDM4E 4354/4885 |
| US-20120328627-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | MEN1 3160/4885KMT2A 3667/4885KDM4E 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.